A provision of the “Inflation Reduction Act” (IRA) could threaten investments in "small molecule" drug development, said a visiting professor at Rutgers University.
Sandip Shah, founder and president of Market Access Solutions and a visiting professor at Rutgers University, is championing a legislative fix to an issue impacting the pharmaceutical industry.